Cambrex Completes Construction and Validation of $3.2-Million Analytical Lab
Cambrex, an East Rutherford, New Jersey-based contract manufacturer of small-molecule active pharmaceutical ingredients, has completed the construction and validation of a new $3.2-million, 11,000-square-foot analytical laboratory at its High Point, North Carolina facility.
The expansion required the sourcing, acquisition, installation, and qualification of more than 20 new analytical instruments, including for high-performance liquid chromatography, mass spectrometers, and support equipment. Cambrex plans to hire 12 new analytical scientists as a result of the investment. The laboratory’s primary function is to broaden analytical support for customer projects being developed and manufactured at the High Point site while forming part of a plan to support Cambrex’s global analytical development and method validation needs.
Cambrex acquired the 35,000-square-foot High Point site, formerly PharmaCore, in October 2016. At the facility, Cambrex produces complex active pharmaceutical ingredients (APIs) and intermediates requiring multi-step synthetic processes in batch sizes from milligrams to 100 kg to support clinical trials from Phase I to Phase III. The site is licensed with the US Drug Enforcement Administration to manufacture Schedule II to Schedule V controlled substances. The acquisition added to Cambrex’s portfolio of small-molecule API services and complemented its large scale, multi-purpose manufacturing facilities in the US and Europe.
This latest expansion at the facility brings the investment at the site to over $5 million since its acquisition by Cambrex and follows the announcement in May 2017 of an increase in pilot-scale manufacturing capacity at the site.